Article
30 Oct 2025
ATA EDGE 2025 Policy Conference
AUTHORS CONTENT
Article
25 Jun 2025
Direct-To-Consumer Drug Ads Are Under Attack – Pharmaceutical Companies Beware
Article
19 Feb 2025
Understanding The Legal Pitfalls Of Virtual Second Opinions: What You Need To Know
Article
20 Nov 2024
New DEA Rule Extends Controlled Substance Telemedicine Prescribing Flexibilities One More Year
Article
18 Nov 2024
Health & Hype Podcast: A Deeper Dive Into DEA Telemedicine Controlled Substances
Article
21 Oct 2024
New DEA Rule Expected To Extend Controlled Substance Telemedicine Prescribing Flexibilities Through 2025
Article
13 May 2024
50-State Survey Of Telehealth Insurance Laws
Article
13 Dec 2023
2024 Predictions: Unveiling The Future Of Healthcare Mergers And Acquisitions
Article
22 Nov 2023
Current Look At Digital Health
Article
13 Nov 2023
Top 5 Rules For Medicare 2024 Remote Patient Monitoring And Remote Therapeutic Monitoring: What Companies Need To Know
Article
22 May 2023
DEA Extends Telemedicine Flexibilities For Prescribing Of Controlled Medications
Article
12 Apr 2023
Foley & Lardner Comment Letter On DEA Telemedicine Controlled Substance Proposed Rule
Article
02 Mar 2023
DEA's Proposed Rules On Telemedicine Controlled Substances Prescribing After The PHE Ends
Article
13 Jan 2023
2023 Forecast For Digital Health Startups And Telemedicine Law
Article
27 Dec 2022
The Future Of Telemedicine Post-PHE And How To Advocate For Change: An Interview With Nathaniel Lacktman
Article
15 Dec 2022
American Hospital Association Urges DEA To Issue Special Registration For Telemedicine Controlled Substances
Article
14 Dec 2022
Episode 23: The Emerging Investigatory Focus On Telehealth: What You Need To Know (Podcast)
Article
02 Dec 2022
CMS Finalizes Changes For Telehealth Services For 2023
Article
01 Dec 2022
Medicare Remote Therapeutic Monitoring: Top FAQs For 2023
Article
13 Nov 2022
Expanded Medicare Telehealth Coverage For Opioid Use Disorder Treatment Services Furnished By Opioid Treatment Programs